Advertisement

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement

Oct

24

Today In Oncology

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome

FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors

Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials

Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening

Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer

Advertisement

© 2026 HSP News Service, L.L.C.